Janak Vadgama is one of the founding members of Qprotyn Inc. and is currently the project manager for the commercialisation of a patented, viscosity-reduction technology for high-concentration mAbs, called HILOPRO®. For the past 3 years, the team has been diligently working towards partnering with biopharma companies across the world and conducting multiple feasibility studies across a range of mono and polyclonal antibodies. Over 10 assests owners in the innovator and biosimilar spaces are currently investigating the HILOPRO® technology for the final formulation.